CN Patent

CN120731076A — 膀胱内施用厄达替尼以用于治疗膀胱癌

Assigned to Liris Biomedical Inc · Expires 2025-09-30 · 1y expired

What this patent protects

本文提供了治疗方法、用于使用的厄达替尼、厄达替尼用于治疗具有一种或多种FGFR改变的膀胱癌的用途，包括将厄达替尼局部递送至患者的膀胱中。

USPTO Abstract

本文提供了治疗方法、用于使用的厄达替尼、厄达替尼用于治疗具有一种或多种FGFR改变的膀胱癌的用途，包括将厄达替尼局部递送至患者的膀胱中。

Drugs covered by this patent

Patent Metadata

Patent number
CN120731076A
Jurisdiction
CN
Classification
—
Expires
2025-09-30
Drug substance claim
No
Drug product claim
No
Assignee
Liris Biomedical Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.